Business Wire

Countdown to the Finals of the ASC24 Student Supercomputer Challenge!

2.4.2024 11:37:00 EEST | Business Wire | Press release

Share

The 2024 ASC Student Supercomputer Challenge (ASC24) finals are scheduled to take place at Shanghai University from April 9 to 13, 2024. Among the over 300 teams representing universities worldwide, only 25 have progressed to the finals. Throughout the competition finals, teams will face a series of challenges including optimizing large language model (LLM) inference, tackling tasks like OpenCAEPoro and GoMars, as well as competing in high-performance benchmarks such as HPL and HPCG. Additionally, teams will engage in group competitions and tackle a mystery application. Each team will present their projects before the jury, contending for prestigious awards including the Champion, Silver Prize, e Prize, and the Highest LINPACK.

The ASC24 Student Supercomputer Challenge Finals

Date

Time

Agenda

April 9

08:00-20:00

Rule Announcement, Cluster Setup/Testing

April 10

08:00-20:00

Cluster Setup/Testing

April 11

08:00-18:00

Competition: HPL & HPCG, Group Competition, LLM

 

April 12

08:00-18:00

Competition: OpenCAEPoro, GoMars, mystery APP

14:00-17:00

The 33rd HPC Connection Workshop

April 13

08:00-12:10

Finalist Teams Presentations before the Jury

15:00-17:30

Closing and awards ceremony

ASC is committed to assisting students in addressing state-of-the-art scientific challenges through the utilization of the most advanced computing products and technologies. This endeavor aims to explore emerging research paradigms and confront the various challenges humanity faces. The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.

The prestigious e Prize will be bestowed upon the winners of the OpenCAEPoro task, which entails simulating the seepage of multiphase fluids, such as oil, gas, and water, particularly within contexts relevant to petroleum extraction. Competitors are tasked with skillfully optimizing large-scale parallel computing processes, emphasizing enhancements in computing performance and parallel efficiency of discrete algorithms.

In the GoMars task, participating teams are challenged with optimizing parallel communication and refining computational load balancing within the dynamic framework of GoMars. GoMars represents a new generation of Mars atmosphere models. The objective is to enhance operational efficiency and achieve more precise predictions of the Martian atmosphere.

In the LLM Inference Optimization Challenge, participating teams are assigned the task of constructing and refining inference engines utilizing the widely employed open-source LLM, AquilaChat2-34B. The primary objective is to expedite inference processes by employing 4-bit or less quantization while maintaining overall accuracy.

Alongside the primary challenges, the finals will include a Group Competition aimed at fostering cross-team collaboration among students. Students will be randomly allocated to one of five groups. Each group will work collectively on the ParaSeis task, employing ParaSeis to simulate seismic wave propagation and refine the algorithm through collaborative communication. The group's performance will be evaluated based on the average score of its constituent teams, with the group achieving the highest score declared as the victor.

The finals will bring together formidable teams from renowned universities, including Peking University - the champion of the 10th ASC onsite finals, the Chinese University of Hong Kong - the champion of the 10th ASC virtual finals, University of Science and Technology of China, Huazhong University of Science and Technology, Shanghai Jiao Tong University, and Friedrich-Alexander-University Erlangen-Nuremberg.

Numerous new teams are set to join the finals, with Shanghai University, Lanzhou University, and Southern University of Science and Technology among them. Excitement surrounds the debut of teams from the National University of Cordoba, Macau University of Science and Technology, and Southwest Petroleum University, making their inaugural ASC finals appearance this year. The enthusiasm of these new contenders promises to elevate the competition, ensuring an intense battle until the very end.

About ASC

The ASC Student Supercomputer Challenge is the world's largest student supercomputer competition, sponsored and organized by the Asia Supercomputer Community with support from experts and institutions across Asia, Europe, and America. The main objectives of ASC are to encourage the exchange and training of young supercomputing talent from different countries, improve supercomputing applications and R&D capacity, boost the development of supercomputing, and promote technical and industrial innovation. The first ASC Student Supercomputer Challenge was held in 2012 and has since attracted over 10,000 undergraduates from all over the world. Learn more for ASC at http://www.asc-events.net/StudentChallenge/index.html.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
media@asc-events.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye